Operator
Good morning, and good afternoon, and welcome to the Novartis Q3 2026 results release conference call and live webcast. Please note that during the presentation, all participants will be in a listen-only mode, and the conference is being recorded.
After the presentation, there will be an opportunity to ask questions by pressing star one and one at any time during the conference. Please limit yourself to one question and return to the queue for any follow-ups.
A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends. With that, I would like to hand over to Ms.
Isabella Zinck, Investor Relations Executive Director. Please go ahead, madam.
Isabella Zinck
Thank you, Sharon. Hi, everyone, and welcome to our Q3 earnings call.
Let me briefly read the safe harbor statement before we can begin. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors.
These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that respectively were filed with and furnished to the US Securities and Exchange Commission.
With that, I'll hand over to Vas.
Vas Narasimhan
Thank you, Isabella. Thanks, everybody, for joining today's call.
If we could move to slide 4. In the quarter, although one second, we're just getting our slides moving here.
In the quarter, Novartis delivered sales growth and core margin expansion. That supported an upgrade to our full-year 2026 bottom-line guidance.
You can see sales were up 4% in constant currency. Core operating income was up 10%.
Mukul will go into the numbers in more detail, but we also had a good margin performance in the quarter. A number of important pipeline milestones.
Notably, of course, as you all know, the remibrutinib data, but also Rapsido received FDA approval. Pluvicto, also with important approvals in the US and China for HSPC.
Pelabresib was also filed in Europe. Del-zota received FDA priority review for DMD44.
Overall, this allowed us to increase our guidance, and we'll go through that in a bit more detail on the call. Moving to the next slide.
Priority brands continue to perform well in the quarter. They were up 29%.
Very strong performance across Kisqali, Kesimpta, Scemblix, and Leqvio. A solid quarter from Cosentyx.
Pluvicto, we're still in the midst of launching in HSPC, we haven't seen that pick up yet, and we'll talk more about that in a bit. Rapsido, also with a very strong performance as well in the quarter.
Moving to slide 6. Kisqali grew 37%, and it continued to outperform the CDK4/6 market.
You can see that our EBC shares, both in US and Germany, are very stable and at a very healthy level. Turning to the US first, 38% growth in the quarter, $3 billion year to date.
We are the leader in EBC, and our NBRx share was up 3 points versus prior quarter. 53% of the patients now on Kisqali are from the exclusive population.
In metastatic, we continue to grow our NBRx share for first-line, which is now at 55%. We continue to grow our prescriber base as well, was up 12% versus prior year and up 44% in early breast cancer.
Outside of the US, we had 35% constant-currency growth, continued leadership in metastatic breast cancer. Our growth is accelerating now in many of our key markets with the early breast cancer launch now approved in 84 countries and reimbursed in 43 countries.
I think some of the benchmarks that demonstrate the performance: Germany, 80% EBC share; UK, 77%; and China, relatively recently after the launch, already reaching 55%. We also released a few weeks or last weekend the NATALEE 6-year data, which showed clinically meaningful overall survival with a hazard ratio of 0.809.
We expect that data to continue to support our growth in the adjuvant setting. I think notably, having that OS data and showing that that CDK4/6 combined with endocrine therapy in those node-zero and node-one patients gives us a strong case to have physicians provide patients with CDK4/6 inhibitors like Kisqali.
Kesimpta grew 22%, fueled by strong demand. US growth was up 21% in the quarter.
Our TRX growth is outpacing the market. We were up 3 points overall in the MS market to 16% share.
We were up 4.5 points in the B-cell class, getting to 27% share. We see a continued trend to prescribing the medicine earlier in earlier lines of therapy.
77% of our NBRx is now first-line or first switch. Outside of the US, also very solid performance.
We have 80% of EU4 patients are from first-line, first switch, and we see strong growth across Europe as well. We continue to generate evidence to demonstrate Kesimpta's activity in various lines of patients as well in longer-term follow-ups.
I think that just allows us to continue to support this medicine and its very strong performance. Moving to slide 8.
Pluvicto grew 20% in constant currencies. It was driven more by the ex-US momentum, as well as by US pretaxane growth.
The US was up 9% in the quarter. That's primarily driven by the mCRPC pretaxane setting with use predominantly after the first ARPI.
The first-line NBRx share is at 15% now, and we expect further share gains over time. That remains our top priority, to continue to drive that early utilization in the mCRPC setting.
We are in the very early days of the PSMAfore addition launch, and I'll cover that in a little bit further detail on the next slide. Outside of the US, we see great performance, 68% growth.
We see accelerating adoption in Europe and many of our key markets: Canada and Japan, as well as early momentum in China. Japan became the fastest market to reach 1,000 patients supported by ongoing site expansion, and also we are building a facility there.
China, we had the approval of the PSMAfore addition indication in August, and we expect that to support growth as well. Moving to slide 9, turning to the PSMAfore addition launch.
I think first, it's important to highlight we have strong foundations in place for the brand. Two-thirds of hormone-sensitive prostate cancer patients are managed by physicians who are already using Pluvicto or are connected to established referral pathways.
We see broad treatment capacity with 9 out of 10 patients within 30 miles of a site. We also see we are also continuing to address the non-clinical barriers.
You can see here the images of both the availability of an infusion and a scaled availability of the prefilled syringe. It's important to note we expect about 5 to 10 weeks of lead time for new patients to be treated, a combination of doing the testing required as well as the scheduling.
We do expect the fastest uptake in higher tumor burden patients, and as well as the de novo patient segments, where there is unmet need versus the current standard of care. We are also expect continued expansion in the community, particularly in urology.
Overall, I'd say we're encouraged by the early uptake indicators, but we do think through quarter four, we will see some uptake, and also important to note we will hit the holidays, Thanksgiving and Christmas. We really think next year is when we'll see further acceleration with the HSPC launch.
Leqvio continued to perform extremely well, up 63% in the quarter. This is demand around the world.
In the US, we're up 60%, 60% outgrowing the advanced lipid-lowering market. Our monthly TRX growth growing well ahead of the market and our main competitor.
I think that's in part driven by Leqvio's persistency and the high compliance rates we're seeing. We see very strong performance in Medicare, which is a good indicator of our performance in buy-and-bill, where we're up to now 22% share.
We also see increasing depth in our key healthcare systems, and we really focus on patients post-event where there's a high propensity to want to get patients to their LDL goal. Then we also had our US label updated with a cardiovascular outcome statement, and we're on track for the ORION-4 and V-TWO-P readouts that are expected in quarter four and in 2027, respectively.
Outside of the US, 65% growth. China growth continues post-NRDL, and we've noted previously very strong growth in China, as well as the same growth in Europe.
Then we're continuing to expand the Leqvio evidence base. V-CHALLENGE was presented, which showed LDL-C lowering better is superior to bempedoic acid.
Moving to slide 11. Scemblix was up 67% driven by strong US momentum.
In the US, we continue to see very strong performance in first-line. We have reached 33% share, and so you can see we're edging towards market leadership, or really at market leadership now, and maintaining leadership as well in later lines, where we expect continued shift in the treatment mix from second, third-line towards first-line.
Very pleased with the US performance. Outside of the US, as well, we're building off a very strong third-line leadership, where we have 77% share across key markets.
The early-line indication is now approved in 69 countries outside of the US. Japan has sustained first-line NBRx leadership at 56% share, and Germany already at 33% share.
Very excited about the trajectory of Scemblix as we move forward. Now Cosentyx had a solid quarter, up 9% in constant currencies.
I think when you net out some of the gross-to-nets, we were in the mid-single-digit growth range, I think that's very solid performance with growth in both HS and the SpA indications. In the US, you can see our HS share is very stable in the high 40s.
The SpA business is remaining resilient, you can see as well in the bottom panel here, our share has steady at 14%. Outside of the US, continued growth in Europe and most emerging markets, stable in China.
We expect continued indication expansion as we move towards the end of the life cycle for Cosentyx. PMR, polymyalgia rheumatica, was approved by the European Commission.
We expect the FDA decision in quarter four, and HS IV was added to the label as well in October. Now Rapsido has had really strong launch momentum.
You see that in quarter three. We also had the additional approval of symptomatic dermographism, which covers about two-thirds of patients with chronic inducible urticaria.
Let's start with CSU. We continue to see the launch trajectory in the US on a steady, strong pace: over 6,000 subscribers, split between allergists and dermatologists; over 15,000 patients treated.
Our NBRx share is about 26%, and that's up about 3 points versus prior quarter. We've been very disciplined with the contracting, so that performance is in the context of about 50% access to label.
We do expect further access expansion over quarter four and into 2027. Of course, as that access expands, we expect continued acceleration on the sales.
Outside of the US, we're now launched in seven markets, and we're steadily getting reimbursement step by step, market by market. We do see strong, early uptake in Germany and China.
When you turn to inducible urticaria, as a reminder, symptomatic dermographism, this is the first ever-approved treatment for this condition. There's about 100,000 US CIndU patients who are uncontrolled on antihistamines out of about 500,000 patients total, and two-thirds of those with SD.
We have 100% overlap with the CSU prescribers, so that should enable us to get to a very efficient launch. We're already rapidly working towards filing the medicine across all three subtypes around the globe.
We're upgrading our peak sales guidance for Rapsido in CSU and CIndU combined to over $4 billion. Moving to the next slide.
We had some important readouts in the quarter, which you're well aware of: remibrutinib, hopefully many of you heard the call on Friday, you know well, I won't belabor, but we'll go a little bit in further review on the next slide, but we were really pleased with the results. We showed that we achieved disease control with outstanding, consistent safety, and the FDA submission is on track for quarter four with a priority review voucher.
Del-desiran, where we didn't meet the end point in HARBOR, but we did have the evidence of clinical activity in the secondary exploratory analyses. We'll present that data in an upcoming medical congress.
We're doing a lot of work now to prepare the next steps and engage with health authorities to chart out the next right steps for the development of the medicine. We did take a partial impairment charge of $1.9 billion, primarily driven by the timeline shifting out by the additional clinical work that will need to be completed.
Then lastly, pelacarsen, the Phase 3 HORIZON study did not meet its primary end point. We will have that full dataset presented at AHA and published in a major medical journal, and I think that will provide further insights into that data.
Further development of DII235, our once-annual siRNA for Lp(a), is still under consideration. All of that taken together, we reaffirmed our 5% to 6% constant-currency sales guidance for '25 to '30 and our mid-single-digit constant-currency long-term growth outlook.
We've done all the modeling, and we feel very comfortable with those numbers. Turning to Remodel, remibrutinib, we were really pleased with this data.
It delivered comprehensive disease control. You can see here on the left all the data that was reviewed, including the 6-month PIRMA, independent of relapse progression impact reduced by 30%.
Very favorable safety profile: robust, consistent, no liver signals, no infection imbalances, nearly 50% fewer discontinuations due to AEs, immunomodulation without B-cell depletion. As we all know, in multiple sclerosis, with so many options, it starts with safety.
If you can't demonstrate a clear, clean safety profile, understandably, neurologists will look for other options. We think having that safety profile and then showing disease control is why we're so excited about the medicine.
The filings are ongoing, as I already mentioned. If you go to slide 16, as a quick review for anyone who was not on the call, we see an opportunity in the naive population, so that's about 30% of that naive population we think would be open to take a medicine like remibrutinib.
In the oral switch population, 40% to 100% of patients over time could prefer remibrutinib given its excellent safety profile and comprehensive disease control. We expect over time, as patients are fully controlled on their anti-CD20s, patients who might want to be switched to an oral medicine, about 45% of those patients in the US.
Then the other segment, which is some of the older injectable medicines, over time we hope to be able to address 100% of that patient population. Outside of the US, we estimate around 38% is addressable.
All of that taken together gives us confidence in a $4 billion-plus medicine with a further upside with the non-relapsing SPMS population. As well, we will read out data in two years on the Ocrevus switch data, which could provide further momentum to these forecasts.
Going to slide 17, I won't go through the slide in detail, but just to highlight, we have multiple readouts coming out in 2026 and a strong catalyst path for 2027. We can cover it on the call with your questions, but all of the milestones that we have for the remainder of this year as well as next year are on track.
Moving to slide 18, and with that, I'll hand it over to Mukul.
Mukul Mehta
Thank you very much, Vas. Good morning, good afternoon, everyone.
I will now share more details on the financials for the quarter. As a reminder, my comments, as always, refer to growth rates in constant currencies, unless otherwise noted.
Moving to slide 19, yeah. In the third quarter, net sales grew 4% to $14.5 billion, while core operating income grew 10% to $6 billion, mainly driven by our growth driven by our growth drivers as well as continued productivity in our business.
Quarter three core operating income margin was at 41.6% of net sales. This is an increase of 2 percentage points versus prior year, and this is mainly driven by gross margin improvements as well as continued productivity initiatives, primarily in our SG&A business SG&A part of our business.
Core EPS grew 8% to $2.46. On a reported basis, in quarter three, operating income was operating income was negatively impacted was $1.8 billion, which is a decline of 61%, mainly due to higher R&D expenses.
The higher R&D spend includes the $1.9 billion partial impairment of del-desiran. This impairment follows the Phase 3 HARBOR readout in DM1, and it reflects our updated assessment of the value of the asset as we evaluate the full dataset and engage with the health authorities on the future development path for the for the product.
Net income for the period was at $1.2 billion, which was a decline of 71%, mainly due to lower operating income and higher interest income. Free cash flow for the period was at $5.1 billion, which is below prior year, primarily due to lower net cash flow coming out of our operating activities.
For the first nine months of the year, net sales were flat, and core operating income declined 2%. Core operating income for the 9-month period was a decline of 0.8 percentage points, and free cash flow for the same period was at $14 billion.
Moving to slide 20, please. We remain committed to our shareholder-friendly capital allocation strategy, balancing disciplined growth investments in the business with meaningful capital distribution back to our shareholders.
In quarter three, we completed the acquisitions of Marex Bio, adding to our early-stage oncology pipeline. We also exercised our option to acquire Ceronax's blood-brain barrier delivery platform, and at the same time, we continued to invest in our internal R&D programs.
On capital distribution front, in the first nine months of the year, we have now repurchased $2.8 billion worth of our shares under the current up-to-$10 billion share buyback program. Please note, we still have $4.9 billion of the program still to be executed.
Slide 21. Moving to guidance.
Given our very strong bottom-line performance in the quarter, we are raising our full-year 2026 guidance for core operating income. We now expect for the full year 2026 core operating income to be in line to growing low single digit.
For reference, this is an upgrade from the previous guidance of core operating income of low-single-digit decline for the full year. At the same time, we are maintaining our full-year guidance on net sales, expecting to grow net sales at low single digit for the year.
For 2026, we also continue to expect core net financial result to be an expense of $1.7 billion and the core tax rate to be around 16.5%. This is in line with our previous guidances for them.
Moving to slide 22, yeah. Beginning of the year, we talked about 2026 as a year of two halves, and with this quarter with this quarter reading out, we're pretty much sticking to that that outlook.
As a reminder, in H1, net sales declined 2%, core operating income declined 7%. Both were impacted by the US Entresto generic erosion.
With a strong Q3 delivery, we now expect a stronger H2 performance. For H2, we expect net sales growing mid to mid to high single digit, and core operating income growing high single to low double digit.
After stepping up in Q3, quarterly sales growth is expected to accelerate further in Q4 as we move beyond the impact of the US Entresto generic erosion. On the core margin, we do expect a decline in Q4 versus Q3.
This reflects the typical year-end phasing of our spend, also higher royalties as growth drivers scale up would play a part, and finally, we will also see the impact of lower other income as a result of the Xolair biosimilars in the US. As a reminder, for 2027, we will provide our full-year guidance with the Q4 results in February next year.
Moving to slide 23, yeah. If exchange rates remain at late October levels, we expect a positive 1 percentage point impact on the full-year net sales and a positive 1 percentage point impact on our full-year core operating income.
If these rates also prevail in 2027, we would expect a negative 1 percentage point impact on top line and no impact on core operating income. As a reminder, we publish updated FX estimates monthly on our website.
That concludes my remarks, and I will hand it back to Vas.
Vas Narasimhan
Great, thank you, Mukul. Turning to slide 25.
We delivered strong growth in the quarter driven by our priority brands and launches, which really shows the replacement power of the business. We've been able to successfully navigate the Entresto, Tasigna, Promacta, Expiry's in the US, demonstrating we grew grew through the year will we will grow through the year, which I think really shows the power of the company.
We advanced the pipeline with positive readouts for our RMS and for Rapsido, as well as Pluvicto label expansions. We're upgrading our full-year guidance for core operating income, and we remain on track to deliver our midterm guidance of 5% to 6% sales in 2025 to 2030 and our long-term growth outlook.
If you go to slide 26. We're excited to also host hopefully many of you at Meet Novartis Management, where we'll provide an update on our midterm guidance from 2026 to 2031, as well as our long-term growth outlook.
We'll update our peak sales potential for key growth drivers. We'll also focus on our mid and late-stage pipeline assets, which we believe will support our long-term growth.
We'll have, as usual, breakout sessions by therapeutic area, and we'll also have a panel session on AI in R&D. We look forward to seeing you there.
With that, we can open the line for questions.
Operator
Thank you. To ask a question, you will need to press star one and one on your telephone and wait for your name to be announced.
Please limit yourself to one question and return to the queue for any follow-ups. To withdraw your question, please press star one and one again.
We will now take the first question. The first question today comes from the line of Sachin Jain from Bank of America.
Please go ahead.
Sachin Jain
Hi, guys. Thanks for taking my questions.
Maybe I'll just kick off, at this time of year it's usually helpful to hear pushes and pulls for '27 growth. Number of launches next year, perhaps some color on what you're most excited about.
Limited LOE, it seems, into next year. Just to wrap the question, is the implied 4Q sales growth rate the best proxy for how to think about '27?
Thank you.
Vas Narasimhan
Thanks, Sachin. I think overall, when you look at next year, as you say, we have less generic headwinds.
We will be navigating the Entresto Europe headwinds, which will just navigate country by country, and so I think that's important to factor in there. We do expect continued dynamic growth from our key growth drivers, brands like Kisqali, Kesimpta, Leqvio, Pluvicto, HSPC, of course, remibrutinib in CSU and CIndU showing acceleration, we'll also Scemblix, and then, of course, we'll also expect the ianalumab launch as well.
A number of things that will provide us the opportunity to have a strong 2027. I think it's important to note in quarter four, we are lapping a number of gross-to-net dynamics in the previous year, I think it'd be best for us to provide more detailed guidance, as always, in January.
I'd say overall, we do expect to get back to where we were, dynamic growth in 2027. Next question, operator?
Operator
Thank you. Your next question comes from the line of James Gordon from Barclays.
Please go ahead.
James Gordon
Hello, James Gordon from Barclays. Thanks for taking the question.
I noted the comment on the Ocrevus to Remi switching study and the focus on switching on Friday's call. Can you just talk that assuming the approval, what do you think the initial rationale for switching would be, and then what do you hope the trial will show?
Because with the caveats of cross-trial comparison, I know the percentage of naive patients might make a difference, Ocrevus does look a bit more effective in terms of relapses and disability. Is that just due to different patients?
What's a good outcome on the trial, and what would that show?
Vas Narasimhan
Absolutely. I think it's important, obviously, we have to complete the study.
Our expectation is that once an anti-CD20 manages the inflammation, particularly in controlling from an MRI standpoint the overall inflammatory burden on the patient, that remibrutinib's ability to achieve disease control, particularly when you look at the disability progression and the PIRMA without complete depletion of B-cell antibodies, which has advantages for patients or if patients no longer want injectable therapies. The idea would be to show patients once they're under control with the anti-CD20, that we can maintain control with MRI as well as other measures.
I think that would give you the opportunity to kind of treat and then maintain with Remi. We're certainly also evaluating to do additional studies with all of the anti-CD20s just to demonstrate that Remi can control regardless of the anti-CD20.
I think when you have patients that have been on anti-CD20s for 5 to 8 years, there is a desire for many patients, and we put our estimates in our forecast to get control through a safe oral medicine. We're also equally excited by new starts in patients who don't want to start on an anti-CD20, switching oral patients who are not feeling like they're or physicians are not comfortable with the level of control, or also switching older injectable patients onto Remi.
We think we have many opportunities to grow the brand. Next question?
Operator
Thank you. Your next question comes from the line of Simon Baker from Rothschild & Co Redburn.
Please go ahead.
Hello, it's Michael for Simon. Thank you very much for the commentary on the SG&A line in 3Q.
I appreciate the seasonality in 4Q, but I'm just wondering what the durability is of that cost reduction and how we should think about that line going forward.
Vas Narasimhan
Mukul?
Mukul Mehta
Yeah. Thanks for the question.
Productivity remains a very, very strong, key pillar of how we run the company. If we look at SG&A for the quarter, we've actually seen SG&A 7% lower in Q3 versus previous year, while the company, from a top-line perspective, has shown a growth of 4%.
This will, as we have previously said, this focus on driving the company forward while looking at productivity, SG&A productivity in particular, as means for us to get to those profit margins of 40%-plus by 2029 latest, would remain a focal point for the company. We've also historically we've said we are spending upwards of $11 billion every year on third-party spend, and this is a year, the last couple of years, I think the extreme focus on those cost categories, which includes things like agency costs, travel costs, consulting or professional services costs, and trying to get some of these categories, we know have been significantly impacted by use of technology, use of AI, and to get both from a demand as well as cost perspective our fair share of the benefits that these categories are deriving is leading us this productivity advantage, which is very durable as we look forward from an outlook perspective for the company.
Vas Narasimhan
Perfect. Thanks, Mukul.
Next question?
Operator
Thank you. Your next question comes from the line of Florent Cespedes from ODDO BHF.
Please go ahead.
Florent Cespedes
Good afternoon. Thank you very much for taking my question.
Florent Cespedes from ODDO BHF. A question related to Leqvio.
Now the ORION-4 results are expected by the end of this year. Could you come back on why it is earlier, it's event-driven?
Also, could you remind us what kind of profile for this product, and if the results are positive, is it fair to assume an acceleration of the sales next year for this product? Thank you.
Vas Narasimhan
Thanks, Florent. We have two studies.
We have the ORION-4, and then we have the VICTORION-2 PREVENT. Both are looking at outcomes.
ORION-4 focused primarily in the UK. The VICTORION-2 PREVENT is a global study.
We expect VICTORION-2 PREVENT to read out next year. I think both studies were designed in such a way to really look at, if you look at the fixed time, following up over a fixed time point, but holding for much longer than the competitor PCSK9s, could you demonstrate a greater CVRR than the high teens that the other PCSK9s demonstrated?
We'll see how that works. It's important to know ORION-4 was partially conducted during the pandemic, I think that's something we're going to have to see how that data plays out.
Nonetheless, we would expect both of these studies, given the LDL lowering is so clear, to ultimately read out positive. I think it would support the continued growth of Leqvio.
We've guided it to be a $4 billion-plus medicine. Very strong and dynamic growth around the globe.
You're seeing that in the US, you're seeing that in China, and we're certainly looking at the peak sales potential of the medicine longer term. I think certainly the outcome studies would support that.
We also have V-1P, which is the primary prevention outcomes trial, which we would expect to read out in 2029. A number of things I think that can support, a number of readouts that can support the longer-term growth of Leqvio.
Next question. Thanks, Florent.
Operator
Thank you. Your next question comes from the line of Graham Parry from Citigroup.
Please go ahead.
Graham Parry
Great, thanks for taking questions. You've now had two quarters in a row with margins above 40%, and I think the guide has been a suggestion to return to above 40% by 2029.
Can you maybe just talk to how we can see that progressing into next year? Could you see 40% earlier than 2029, and maybe even into next year?
Then if I could just throw in a quick follow-up on the Pluvicto and Do you see any potential impact of the draft proposed new DGTR 70 guidelines for patient release after radioligand therapy, and any impact on the ability of sites to administer radioligand therapies in general? Thank you.
Vas Narasimhan
Thanks, Graham. On the margin, Mukul?
Mukul Mehta
Yeah. Thanks for the question, Graham.
We remain confident on on our commitment to get to 40% margin by 2029. The main drivers of getting us for us to get back to that would be continued momentum on the top line as well as continued productivity movements.
As I've previously answered, I think most of it would come from SG&A as a percentage of sales. Now what we have to understand is, as Vas mentioned previously, I think during during this time, we'd also have to deal with Entresto ex-US genericization as well as the US Xolair biosimilar competition coming and hence impacting other revenue, which is essentially pretty much a dollar on other revenue all comes down to the bottom line.
I think give or take, we're talking of between 2 to 2 to 2.5% percentage of erosion to deal with from this other revenue perspective. I think yes, we've had a fantastic performance year to date at, I think, yeah, year-to-date numbers of 40.1% from a margin perspective, but we do expect Q4 to be lower, as it has always been, with the spend going up in Q4.
Then from thereon, I think we would see continued investment in R&D, continued productivity measures, especially on the SG&A line, erosion on the margin as a result of other revenue wiping off or other revenue because of Xolair biosimilar wiping out, and then we getting back to 40% latest by 2029. Then,
Vas Narasimhan
Graham, on the Pluvicto, we don't see an impact from this regulation. We did provide input.
We don't see any changes in site behavior from what we can tell. Certainly, we're working with the authorities to continue to educate them on the appropriate standards for radiation exposure and manage that appropriately.
We don't see that. If anything, we're having ongoing programs to look at Pluvicto readministration in multiple settings.
Could it be given in HSPC and in mCRPC to give physicians more confidence that they could use Pluvicto and not have to reserve it for patients who are further progressing? I will keep you, of course, posted if we see anything different.
At the moment, no impact from those regulations. Next question?
Operator
Thank you. Your next question comes from the line of Kerry Holford from Berenberg.
Please go ahead.
Kerry Holford
Thank you for taking the question. Del-desiran, I wonder, Vas, if you could give us a little bit more insight into the plans post HARBOR.
Will you run another Phase 3? Are you considering different end points?
Updates on the timelines there. Also on the impairment, noting it was only around a quarter of the total carrying value, perhaps a surprise that was not larger.
You did mention the delay to launch. Was that the key reason for the writedown?
Should we assume there's been minimal change to your probability assumptions, your peak assumptions for that product? Thank you.
Vas Narasimhan
Thanks, Kerry. With del-desiran, it's early days.
I think it's hard for us, I think, to give you too much color. What we're doing is a deep analysis of the trial data and really trying to learn as much as we can.
We have an ongoing open-label extension, which is also providing us further insights and using that to further understand the profile of the medicine. I think that will inform our approach for the next steps in development.
I think once we have clarity and really alignment with regulators, we'll provide updates on what that next study will look like. We still assume we'll need to do another Phase 3 study to ultimately bring the medicine to patients.
In terms of the math for the write-off, when you have to do an additional study, of course, a Phase 3 program, the timelines are the timelines. We assume a similar probability of success.
We, of course, make various assumptions, scenario assumptions with respect to competition, and that's how we arrive at the number. I would note that we also, when we have accelerations, it may not always be the case, we mark up assets as well.
I wouldn't read too much into these numbers. I think it's more important that we just keep working as fast as we can to get the medicine forward to patients, and that's what we're focused on.
Next question?
Operator
Thank you. Your next question comes from the line of Steve Scala from TD Cowen.
Please go ahead.
Steve Scala
Oh, thank you so much. On the second-quarter call, Novartis said that ianalumab was on track for a Q3 approval, we're now a third of the way through Q4 and no news.
On the second-quarter call, the company also referred to data FDA was requesting, real-time requests, at least as of that point. Curious on the reason for the delay and what is the outlook?
Thank you.
Vas Narasimhan
Thanks, Steve. We're in ongoing label discussions with FDA, and providing them the analyses that they're requesting to finalize their review as well as to support them on their approach to labeling.
We do expect an action by the end of the year. I'd say everything is on track, and we're providing that information on a real-time basis.
We look forward to giving you an update. We do expect the action before the end of the year.
Next question?
Operator
Thank you. Your next question comes from the line of James Quigley from Goldman Sachs.
Please go ahead.
James Quigley
Great. Thank you for taking my questions.
On Pluvicto, you flagged the speed of uptake for PSMAfore addition, which is which is helpful. For the past four quarters or so in the US, sales have been flat.
Is is PSMA4 is the PSMAfore indication sort of fully penetrated from a revenue perspective in the US? How should we think about the impact here with respect to PSMAfore addition?
Should we expect a similar pattern with a step-up in Q4 or the first half and then to plateau relatively quickly, and then ex-US will drive most of the growth? Interested on on how you think that's going to play out, particularly with respect to Europe, following the withdrawal of the application for PSMAfore addition.
Also a very, very quick follow-up on Steve's question on on ianalumab. How do you expect the market to develop given the positive data from from a competitor?
I know we haven't seen their their SI benefit, but how are you thinking about the potential scenarios around that? Thank you.
Vas Narasimhan
Thanks, James. On Pluvicto, I think there's a couple dynamics.
We see most of the demand, as I noted, in the mCRPC setting. We continue to work to get physicians not to cycle ARPI's and to use Pluvicto after the first ARPI where it is indicated.
That's something we're working through. I think we do very well after multiple rounds of cycling, and we're trying to get earlier and earlier in the treatment paradigm.
We do think there's a lot more opportunity in the mCRPC, but it does take time to change those physician behaviors, particularly in the community. We do want to see continued growth in mCRPC.
Then on top of that, HSPC as well, we do expect there to be steady uptake. I do think that it's important to note this is going to take time to develop.
There's certain patient groups that physicians are particularly interested in, I mentioned high burden patients or patients who are de novo. I think over time, as physicians get more comfortable in the community in urology setting, we'll hopefully see broader use for Pluvicto in that setting, and that could then also take us up to further growth further sales momentum.
As you also note, I would say particularly we're excited about the growth we see in Japan and China, where we see a lot of dynamic growth on the outlook for the brand, and could be quite substantial. We also do see very solid performance in certain European markets, markets like France, and to some extent some of our other European markets.
The reason, of course, we always think through our indications in Europe is just because of some of the pricing considerations, and sometimes it's not, unfortunately, the best move to add additional indications depending on what the various reimbursement agency's perspectives are on the trials. We have to make those decisions in real time.
All of that taken together, no change on our peak sales outlook for Pluvicto. We think this is just the nature of, you see a ramp initially, and then you have a slower climb as you try to change behavior in the physician offices.
Now with respect to Sjögren's, very hard to comment. Of course, we don't know the competitor's data in detail, and of course, they ran a different program.
I think we need to also understand their data as well in the high symptom burden patients. We're running a separate study in the high symptom burden patients, where we ran duplicate studies in the systemic patients, replicate studies.
I think the profiles of the studies are a little bit different. I think we'll have to see.
Also, the mechanisms are very different: tissue B-cell depletion with ianalumab and anti-CD40 ligand is targeting a different pathway. I think there also could be nuances as to which patients respond.
All to be determined, but hard to know until we see the full dataset.
James Quigley
Great. Thank you.
Vas Narasimhan
Next question?
Operator
Thank you. Your next question comes from the line of Trung Huynh from RBC.
Please go ahead.
Trung Huynh
Hi, guys. Thanks for taking my question.
Just on your slide on the Meet the Management, you've noted this focus on mid-stage and late-stage pipeline assets to support growth. I don't want you to give too much away here, but can you frame which three or four Phase 2 assets you believe to be the next assets for the next decade?
At the event, will you help with guidelines for peak sales, timelines, anything to really help us start thinking about these for our forecasts? Thank you.
Vas Narasimhan
I want you guys to actually come, I won't get into all the details. I think we have a number of programs, first advancing in Phase 3 or expanding programs that we've not talked a lot about.
I think certainly [abelacimab?] is high on our mind, and trying to describe not only the pivotal study, but also the full spectrum of indications that we'll have pursuing for [abelacimab?]
. It's a drug we're very excited about.
Programs like actinium, PSMA, pelabresib, we haven't spoken a lot about, but we're advancing pelabresib. Of course, we can provide further updates on some of the programs we acquired from Avidity.
Then there's going to be additional mid-stage programs that we've not previously gone into. I don't want to get into it here on the call, but I think our goal would be, in each one of the therapeutic areas, to identify, let's call it one to three assets that we would want to get you guys to start thinking about.
We'll provide you at least some perspective on how we think about it. Peak sales, we tend to reserve to indicate drugs where we actually have an approval in at least one indication.
We will provide updates on peak sales for our growth drivers as well as recent launches as well. Next question?
Operator
Thank you. Your next question comes from the line of Thibault Boutherin from Morgan Stanley.
Please go ahead.
Thibault Boutherin
Yes, thank you very much. Just on the cardiovascular pipeline, the Lp(a) siRNA follow-on drug, DII235, you mentioned is under assessment.
What kind of data are you waiting for to make a decision? Are you waiting for competitor data on Lp(a) following the lack of signal that we've seen with pelacarsen?
Similar for pacibekitug, IL-6 in ASCVD, we obviously had disappointing data from ziltivekimab in ASCVD and CKD. What could be the pass forward here for the IL-6?
Vas Narasimhan
Yep. Thanks a lot for the question.
I think on Lp(a), we don't need to wait for necessarily competitor readouts. I think we have a lot of insights based on the study, and you all will see that from Dr.
Nissen at AHA. I think we have a good understanding, and I think we're just trying to evaluate, is there a patient segment where we think that the medicine could make sense, and how best to then ultimately run that study?
I think that assessment is just ongoing. I don't want to supersede his presentation and the publication of the data, but I think we still have a lot of things to think through as we learn from that very large, robust dataset from the HORIZON trial.
I think your point on pacibekitug is well taken. We are carefully assessing, given the readouts that we've seen from our competitor, what is a reasonable development path?
We're still working through that and trying to identify, is there a patient group? We focus on the ACS patients, patients who are post- an acute coronary event.
Is there a trial design? Is there something where we believe we have conviction to think that there's a reasonable probability of success?
I think given what we've seen, anything we do would have to be considered a high-risk, high-reward approach, but that we're willing, of course, to take those bets in cardiovascular as appropriate. That's still something we're working through.
We can discuss that further in Meet the Management. We still have to, I think, do some more analysis and thinking to finalize that Phase 3 program.
Next question?
Operator
Thank you. Your next question comes from the line of Matthew Weston from UBS.
Please go ahead.
Matthew Weston
Thanks very much. Vas, you raised the Remi peak for CSU and CIndU to $4 billion-plus, but you said wait for the CMD for other peak increases.
I'm just curious as to why the two-tier timing. Is it because you wanted to reinforce the overall potential of Remi given maybe the market expected more for MS?
I'm just interested.
Vas Narasimhan
Matthew, I think our thinking is not too sophisticated here. $4 billion for CSU and CIndU, $4 billion for the current MS readout, and so not including non-relapsing SPMS.
That indeed equals $8 billion-plus. I think once we see the HS readouts, that would help us then, I think, inform kind of the overall number that we want to head to.
We acknowledge we have food allergy as well, we have chronic pruritus of unknown origin, we have rosacea. As our standard is usually not to include peak sales for drugs that have not actually read out positive in the Phase 3 studies.
Any Remi peak sales we give has to be based on indications that have read out positive. HS would then inform, I think, our thinking on the overall Remi peak sales, and then if we ultimately were to be successful in food allergy, we would revisit the peak sales, and then CPUO and rosacea.
Does that make sense?
Matthew Weston
It does. Thank you.
Vas Narasimhan
Thank you. Next question?
Operator
Thank you. Your next question comes from the line of Peter Verdult from BNP Paribas.
Please go ahead.
Peter Verdult
Hi. Peter Verdult, BNP Paribas.
Apologies for the any background noise, traveling back from ESMO. Just the one for you, Vas.
When we think about, yeah, the key debate in the market, the mid-aspiration of growth beyond 2030, and what could help drive that from the pipeline. One asset we haven't talked about is rap-cel, just wanted to check in.
Is there anything incremental to say on those autoimmune studies that were paused over the summer getting restarted? I know when we saw you in September, you were talking about patients and docs clamoring to get these trials restarted, but are regulators moving at the same speed?
Is there anything you can say there? Thank you.
Vas Narasimhan
Thanks, Peter. I think we're still working through that safety assessment.
We have to obviously now, because we're on hold, prepare a full package and ultimately engage with regulators. I don't have a specific timeline.
All I can say, we're very committed. We've seen the efficacy, and it is impressive in almost every indication that we've taken the medicine into.
I think now we just need to figure out exactly what is the right approach to mitigate this particular safety issue that we've identified, the ICANS. I think that will take us a few more months, is probably the best guess I have at this point, and then we hope to get those studies started up again next year.
I think on the market debate, I think to your earlier part of the question, our plan certainly at Meet the Management is at least to outline for you how we see, from at least from where we sit today in 2026, how that first part of the 2030s will unfold, where you've got the LOEs, but then what we see from our in-line brands that have protection into the 2030s, what we have from the new launches that we have coming online, what we see from the pipeline, and help you guys bridge to why we're where we're at in the mid-2030s, 2035, 2036, versus the few calls there are right now for the consensus.
Peter Verdult
Thank you.
Vas Narasimhan
Next question?
Operator
Thank you. Your next question comes from the line of Michael Leuchten from Jefferies.
Please go ahead.
Michael Leuchten
Thank you. Vas, if I could please go back to ianalumab in Sjögren's.
Just wondering if I could push a little bit further on the inconsistency that we had in the data around regulatory SI and clinical SI, and there were sort of subgroups of the end points that worked better than others. When you talk to label discussions with the FDA, is it about the definition of the end points and where the benefit is, or is it about defining patient populations that should be the target population?
Vas Narasimhan
I think it's not about the end points. The end point results are robust.
This is about how best to describe the benefits, which patients derive the greatest benefit, I think is the best way to put it. We're providing them the necessary data to do that in the way they see best within the label.
That's probably as much as we know as well, but we're providing all of that information as we continue to try to finalize the label with the agency.
Michael Leuchten
Thank you.
Operator
Thank you. Your next question comes from the line of Richard Vosser from JPMorgan.
Richard Vosser
Hi, thanks for taking my question. Quick question on going back to Remi in HS.
We've obviously seen in the last week or so the lutikizumab data, which came in a little bit on the underwhelming side. Just Vas' latest thinking on Remi in HS, what types of patients have you got in the trial?
I think there was differences in between the two doses in Phase 2. Just latest thoughts there.
Thanks very much.
Vas Narasimhan
Thanks, Richard. We obviously saw that data.
As in immunology studies, particularly in a situation like this where the placebo group can move around quite a bit, we'll have to see. I think our hope is that if we can show efficacy in the HiSCR75, also 50, but really the 75, in the range of biologics as a highly safe oral drug, especially if we can show that that persists over time, this can be a very attractive medicine.
Then, of course, the upside would be we can demonstrate what we showed in the Phase 2 data, where we had at least cross-trial comparison superiority to the biologics. There's a lot of this will come down to how the placebo group behaves, and we think we've done all of the right things to manage that, but that is the kind of wild card in this whole situation.
We'll have to see, but we have the two readouts sequentially, and then we'll provide that update, hopefully. I think we should hopefully get this done before Meet the Management.
Next question?
Operator
Thank you. Your next question comes from the line of Rajesh Kumar from HSBC.
Please go ahead.
Rajesh Kumar
Hi, thanks for taking my question. Just thinking through 2027, I know you're going to provide guidance in January, but if we think of the mechanics of it, gross margin-wise, should we sort of assume that to be the trough, yeah?
Then we had a very strong performance of SG&A seasonally that should reverse in fourth quarter a bit. On a run-rate basis, does $14 billion order of magnitude for '27 looks like a sensible ballpark number which consensus currently is modeling?
Vas Narasimhan
Go ahead, Mukul.
Mukul Mehta
Yeah. Rajesh, you were talking about your estimates for next year.
I think this is, as we've previously said, I think we would wait for Q4 to give our estimates. From a midterm perspective, I think we stand 2025-'30, 5% to 6%.
We've historically said that this will not be a linear growth path. There will be years like 2026, which will be more impacted because of genericization, and then there will be years like '27, where we will have less generic impact.
We would wait for end of the year to provide the necessary guidance for next year, yeah.
Rajesh Kumar
No, I appreciate that. The implicit question was that the SG&A we have seen the reduction we have seen in third quarter,
Mukul Mehta
are
Rajesh Kumar
there any structural elements there that we need to factor in when we are thinking about the future, like AI-driven productivity or certain cost reductions which means for future, you won't have those costs, or all of it is at the moment cost containment as you go through the LOE phase?
Mukul Mehta
Yeah. I think, Rajesh, okay, sorry, I got it now.
On SG&A as a percentage of sales, I think we've historically said that that's the place where our margin improvement over the next four years is going to come. As we spoke about getting to 40% by 2029, we've actually said that that margin improvement will come from SG&A.
If I look at Q3, I think one taking one quarter and saying that's the estimate now for the next three years is annualizing it for the full year is not the right thing, but if we needed a data point to say how do we get to that 40% margin by 2029 through SG&A, then I think here is a good data point that we have that we are absolutely on the right path, is what I'd say.
Rajesh Kumar
Very clear, sir. Thank you very much.
Operator
Thank you.
Vas Narasimhan
Next question?
Operator
Thank you. Your next question comes from the line of Urban Poutzer from ZKB.
Please go ahead.
Urban Fritsche
Yes, hi, everybody. Thanks for taking my question.
Just a question on asset allocation. You have been stepping up share buybacks quite a bit after del-desiran failure.
What's your thinking going forward with those share buybacks? Will they stay on that level, also taking into account that your shares have been nicely rebounded?
How do you think about having those gaps open now from the recent failures and filling those versus share buybacks? That's my question.
Thanks.
Vas Narasimhan
Maybe on the first part of the question, on the pace of the buybacks, Mukul?
Mukul Mehta
Yeah. As I think share we share buyback is a is a clear pillar of our overall capital allocation priority, and this will not change going forward.
You also know that we do the share buybacks on the secondary line here in Switzerland, which are clearly we have certain constraints in terms of the amount of volumes that can go. We do this share buyback through independent independent partner and independent bank who does it, and we modulate how much we buy depending on market conditions.
This is what we have done in the past, and we would continue to do so. Absolutely right that as the as the share price took a inordinate, significant reduction, we actually increased the pace, but we have to I think going forward, we would continue to modulate it up or down, and we remain committed to doing getting to that $10 billion share buyback program by end of 2027.
Vas Narasimhan
Then I think on the broader capital allocation point versus M&A, there's no change in our thinking. We grow the dividend in Swiss francs every year, as we have now done for almost 30 years.
We are at for 30 years. We are committed to investing in the core business.
We do primarily bolt-on M&A under $2 billion, very selectively doing larger deals when we see something that's very compelling. Then with excess capital, we're committed to also returning capital to shareholders via the share buyback program.
All four pillars are things that are priorities for us. We do them in balance, and no change based on any of the recent events.
Next question?
Operator
Thank you. Your next question comes from the line of Seamus Fernandez from Guggenheim.
Please go ahead.
Seamus Fernandez
Oh, thanks so much for the question. My question is actually on your approach in kidney disease.
Vas, I was just hoping, you have a number of assets in the space across IgAN and other immunologic disorders on the kidney disease side of things, but just wanted to get a better sense of how you see Novartis' presence in kidney disease evolving from here, just given the intensifying competitive landscape in particular. Thanks.
Vas Narasimhan
Thanks, Seamus. I think clearly the anti-APRILs have changed the landscape.
I think the data has been clear and compelling, and really demonstrated that they are the standard of care. I think now we continue to believe Vanrafia will be a blockbuster medicine.
We also continue to believe Fabhalta across all of its various indications will get to the $3 billion sales we've outlined for that medicine. I do think we've had to think carefully now on how to position these medicines in the context of the anti-APRILs.
I think zigakibart, of course, we'll have the readout next year. That'll be an important milestone for us, and then to determine how best to kind of position these medicines in the context of potentially having four different anti-APRILs in the market.
That's kind of how we're looking at IgAN. I would say outside of the US, the story is very different.
In places like Japan and China, where we have very strong positions, we're seeing significant opportunities for our IgAN portfolio, also in certain other markets around the globe. This will a little bit be geographically tailored for IgAN.
We remain committed to adult polycystic kidney disease. We have farabursen, we're continuing to advance that in the clinic.
We also have ongoing efforts for other rare renal diseases, and so that those generally are early-stage, and that continues to be a focus area as well. That's kind of how we're thinking about it, but we're in a state of flux at the moment as we kind of think through how best to position Vanrafia and Fabhalta in the context of the anti-APRILs.
Next question?
Operator
Thank you. We will now start round two for the Q&A.
Please limit yourself to one question and return to the queue for any follow-ups. The next question comes from the line of Steve Scala from TD Cowen.
Please go ahead. Oh,
Steve Scala
thank you so much. Regarding Kisqali, what portion of growth is attributed to the adjuvant setting, and what is the risk that Roche's giredestrant captures a majority of that growth?
Is Novartis' defense solely based on having achieved OS and the duration of experience with Kisqali? That's a good argument, but it didn't work for Lilly with Verzenio when you were launching Kisqali.
Thank you.
Vas Narasimhan
Thanks, Steve. We have very solid growth across all lines.
We can get you the exact number, but I think metastatic continues to be an area where we're strong with our NBRx share, as I mentioned, in the first-line setting. As I mentioned, over half of the patients are coming from the node-zero, node-one, where we're alone, and then the other half in the early breast cancer setting from the overlapping population with our competitor.
The way we think about it is we have a couple of things going for us. One, as we have a very long history here in the market, and we do believe that physicians trust endocrine therapy that they've had established for many years, maybe more than is currently being assumed in the market, and so I think that's not an insignificant task.
We've learned that in many many parts of different therapeutic areas. To displace established therapies that are safe and effective is not always a straightforward task.
Second, with Kisqali plus endocrine therapy, you do have a long history, and you have OS data now, which we think is something that we can use to significant effect, especially when you look at the overall benefits here for patients. This is something that's proven.
You have the OS as well. Then lastly, we continue to work to generate data with Kisqali and the appropriate oral SERDs to show that you could also use these in combination as well.
We're, of course, thinking about that for our CDK2 and CDK2/4, CDK4 portfolio as well, to make sure we have those combination data. We think when you look from here, '27, '28, '29, 2030, we will be able to manage this and achieve our $10 billion peak sales.
You yourself can see where Kisqali already is. Then I would say outside of the US should not be forgotten.
We do extremely well. You saw very high shares outside of the US given our strength ex-US.
We're not MFN constrained, we're not constrained by any of these other dynamics. China, NRDL, is obviously helping us quite a bit as well.
Taken together, we feel very comfortable with the peak sales guidance on Kisqali.
Steve Scala
Thank you.
Vas Narasimhan
Next question?
Operator
Thank you. Your next question comes from the line of Graham Parry from Citigroup.
Please go ahead.
Graham Parry
Hi, great, thanks for taking my follow-up. Just on Entresto European generics, I think the regulatory data protection expires next month, but I think there were some SPC rulings on your SPCs to 2028 that might provide some protection in additional countries.
Maybe you could just help us understand sort of timing of expected launches across different European territories, and if they differ at all. Thank you.
Vas Narasimhan
Right now, you're correct, Graham, SPC expires next month. We don't currently expect any impacts in quarter four, and then I think we're continuing to now work through the various cases in individual countries.
I think each country has a different dynamic, and so I think it's really a country-by-country situation where we do have to make the filing for an injunction, and then of course then goes through the various legal But we are absolutely committed to defending our patents in every one of these markets, and we believe we have a case to be made. We're absolutely doing our best to extend based on those valid patents Entresto's protection across Europe.
For obvious reasons, I don't want to get into individual countries at this point in time. Then, of course, when we have clarity, we will of course can fold that into any updates that we give in the various quarters.
Graham Parry
Great. Thank you.
Next question?
Operator
Thank you. Your next question comes from the line of Thibault Boutherin from Morgan Stanley.
Please go ahead.
Thibault Boutherin
Thank you very much. Just a quick question on Kesimpta and Briumvi's subscription in the US.
Your main competitor has been noting increasing competition from Briumvi in the US market. I know it's a relatively different channel, but can you comment if you notice any shift in competitive intensity in the US, any color here, because you seem to paint a different picture for Kesimpta in the US?
Vas Narasimhan
Thanks for the question. I think for Kesimpta, what we do see is the market has split into physicians who are more oriented towards buy-and-bill, and there is a competitive dynamic there.
As you're aware, in the self-administration market, we've been able to go on our own, which is why our market share high 20s for the B-cell class, and then continues to grow overall. We are working very hard to get the readout for the Q2M Kesimpta next year, and we're on track for that, and then continue to look at other life cycle management options.
Of course, we have remibrutinib as well now coming as well in MS. We don't see impacts from the injectable competitor or the various at-home infusions and pumps, etc., for Kesimpta right now.
We are watching closely the potential launch of a subcu from one of the competitors, but I think also there, it's very important to look at safety profile. Can you get around the injection site reactions and any sort of premedication?
Kesimpta is a very clean, very comfortable for neurologists to use. We're not expecting that to disrupt the Kesimpta peak sales outlook, and so I think overall, we're very pleased.
Then again, outside of the US, Kesimpta performs extremely well. In many markets, we have 80%-plus share for Kesimpta.
I think it just demonstrates that the brand is performing extremely well. Next question?
Operator
Thank you. Your next question comes from the line of Sachin Jain from Bank of America.
Please go ahead.
Sachin Jain
Hi, thanks for the follow-on. Just after an update on [Votaplam?]
and FSHD, timing of the FDA meetings and how are those interactions going? Thank you.
Vas Narasimhan
Thanks, Sachin. We do expect the [Votaplam?]
engagement in the coming months, and I think then appropriate updates will happen based on the 2-year follow-up data, and I think particularly focused on the intermediate advanced patients, to the intermediate disease patients. With FSHD, we are expecting the FDA meeting, again, before the end of the year, and I think we're doing our best to make the case for an accelerated approval filing based on the data package we have, which we think is compelling.
Of course, this is first-in-class medicine, a disease that's never had a therapy before, and we of course have to have that discussion with FDA. I will also add in that before the end of the year, we also expect pelabresib potential accelerated approval discussion based on MANIFEST-2.
We're running MANIFEST-3 right now, so that would give us confirmation that we if the FDA agrees, which we still have to see, would be able to file this medicine as well. Pelabresib would be a nice uplift as well, and something we're quite excited about.
Then lastly, since it's not been asked, we did pass the [abelacimab?] interim result.
It was a very, very high bar, and so ultimately the study will continue, but without any changes. We feel really good about that, and excited now to get that study to completion.
As I mentioned, we already have a program I think I've mentioned in other settings that we are planning a study to start next year in secondary stroke prevention, and also evaluating additional clinical trials for [abelacimab?] , which we can discuss further at Meet the Management.
Next question?
Operator
Thank you. Your next question comes from the line of Richard Vosser from JPMorgan.
Richard Culpeper
Hi, thanks for taking my follow-up. Just wanted to go back to the Xolair erosion.
I think your partner was suggesting that Xolair might not go down next year, just wanted some clarification or clarity on the profit share agreement and how you're thinking about that going into '27. Thanks very much.
Mukul Mehta
Thanks, Richard. Richard, I think we can work with the assumptions that we have right now in the market.
We know that there is biosimilar right now in the market. There's potential for further biosimilars to come.
I think as we go into the next couple of years, as there will be more biosimilar activity, Xolair sales will go down, and hence the profit contribution that we have that comes to us in terms of other revenue will go down, which essentially that other revenue comes into our core operating income, that puts this pressure that we will have. Now you're absolutely right that if the amount of biosimilar impact next year is limited, then we would also have that impact that we would have on the margin would also be limited for us.
I think we'd have to see how this pans out in terms of biosimilar activity. What is very clear is that we would see pressure on the margin in the next couple of years as a result of Xolair biosimilars in the US.
Does that answer the question, Richard?
Richard Culpeper
Yes, it does. Super helpful.
Thank you very much. Sorry for the background noise.
Vas Narasimhan
Thank you. Next question?
Operator
Thank you. We will now take our last question for today.
The question comes from the line of Rajesh Kumar from HSBC. Please go ahead.
Rajesh, your line is on mute.
Rajesh Kumar
Hi. Just in terms of your comment about share buyback, I know it's a core pillar of how you add value.
What would you need to see in an acquisition opportunity for you to rethink that capital allocation decision to buy or to business development would be worth more than share buyback? What would change your mind?
Vas Narasimhan
I think it's for us, given the free cash flow that we generate and our core operating income outlook, a 5-year plan, we don't see this as a trade-off at all. We can do the M&A deals that we find attractive and maintain share buybacks.
Since we're not contemplating deals that are so large that we'd have to compromise our share buybacks, we don't see this as a trade-off. Actually, we think it's something that can all work.
Then, we of course have to pace things based on a number of factors: financing costs, debt load, etc. I think overall, this is not a trade-off.
This is a balanced approach that we plan to maintain over time. Very good.
Thank you, everybody, for joining. Always appreciate it.
Always excellent questions. We hope we got to almost all of your questions.
We'll look forward to seeing everybody at Meet Novartis Management, where you'll get to interact, as always, with our R&D teams, our commercial teams. We think it's a great event.
We always look forward to it, and always appreciate all of your participation. Thank you very much, and we'll see you in a few weeks.
Operator
Thank you. This concludes today's conference call.
Thank you for participating. You may now disconnect.
Already premium?